Diagnosis and treatment of myelodysplastic syndromes: a review
MA Sekeres, J Taylor - Jama, 2022 - jamanetwork.com
Importance Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic
syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow …
syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow …
Artificial intelligence-driven biomedical genomics
As genomic research becomes more complex and data-rich, artificial intelligence (AI) has
emerged as a crucial tool for processing and analyzing high-dimensional genomic data …
emerged as a crucial tool for processing and analyzing high-dimensional genomic data …
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
The classification of myeloid neoplasms and acute leukemias was last updated in 2016
within a collaboration between the World Health Organization (WHO), the Society for …
within a collaboration between the World Health Organization (WHO), the Society for …
Molecular international prognostic scoring system for myelodysplastic syndromes
E Bernard, H Tuechler, PL Greenberg… - NEJM …, 2022 - evidence.nejm.org
Background Risk stratification and therapeutic decision-making for myelodysplastic
syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS …
syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS …
Prediction of risk for myeloid malignancy in clonal hematopoiesis
Background Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of
undetermined significance (CCUS) are defined by somatic mutations in genes associated …
undetermined significance (CCUS) are defined by somatic mutations in genes associated …
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
E Estey, RP Hasserjian… - Blood, The Journal of the …, 2022 - ashpublications.org
Patients with acute myeloid leukemia (AML) have conventionally received more intense
therapy than patients with myelodysplastic syndrome (MDS). Although less intense …
therapy than patients with myelodysplastic syndrome (MDS). Although less intense …
Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes
E Sauta, M Robin, M Bersanelli, E Travaglino… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in
which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular …
which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular …
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
AM Zeidan, U Platzbecker… - Blood, The Journal …, 2023 - ashpublications.org
Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable
clinical presentations and outcomes. The initial response criteria developed by the …
clinical presentations and outcomes. The initial response criteria developed by the …
Emerging roles of spliceosome in cancer and immunity
Precursor messenger RNA (pre-mRNA) splicing is catalyzed by an intricate
ribonucleoprotein complex called the spliceosome. Although the spliceosome is considered …
ribonucleoprotein complex called the spliceosome. Although the spliceosome is considered …
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia
B Falini, MP Martelli - American Journal of Hematology, 2023 - Wiley Online Library
Several editions of the World Health Organization (WHO) classifications of lympho‐
hemopoietic neoplasms in 2001, 2008, and 2016 served as the international standard for …
hemopoietic neoplasms in 2001, 2008, and 2016 served as the international standard for …